Extended Data Fig. 6: Comparison of irAEs and clinical responses to ICB.
(a) Coincidence of irAE onset and clinical benefit across the major 12 irAE types. P values adjusted by FDR were obtained from the two-sided Chi-squared test (N = 357 patients). (b) Comparison of Any irAEs and ICB responses in terms of differential gene expression in the PRE and EDT samples. Nominal P values of differential gene expression were obtained between Any irAE cases and control samples and between responders and non-responders (Any irAE, N = 105 patients, Control, N = 53 patients, Responder, N = 32 patients, Non-responder, N = 126 patients). (c) Comparison of the expression levels of neutrophil marker genes between responders and non-responders in the PRE and EDT samples (N = 158 patients, PRE and EDT matched). Nominal P values were calculated for normalized mean values by the two-sided Mann-Whitney U test. *P < 0.05. (d) Comparison of Any irAEs and ICB responses in terms of associations with germline variants (N = 321 patients). Only common SNVs were included here. Nominal P values were obtained from two-sided multivariable regression. (e) Manhattan plot for germline variants and HLA types associated with the ICB response. The red and blue horizontal dashed lines indicate a P value of 0.01 and 0.05, respectively. Orange and blue dots indicate SNVs and CNVs, respectively, with P < 0.01. Red dots represent the top 10 SNVs with the highest Shapley value. Nominal P values were obtained from two-sided multivariable regression (N = 321 patients).
